Highlights:

• Digital Health Subsidiary, Tech2Heal SAS, Reports Multiple Contracts and Pilot Studies Signed Since January Launch
• Increasing Traction Achieved in Europe and South America in Multiple Healthcare Verticals

TORONTO, ON / ACCESSWIRE / August 3, 2023 / AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB), a leading company committed to acquiring and advancing Artificial Intelligence/Machine Learning technologies that address urgent societal needs, is pleased to report that its minority-owned subsidiary, Tech2Heal SAS, has made significant strides following the successful launch of their flagship product, the AI-driven Alakin Digital Health Platform. Since its introduction into the market in January of 2023, the Alakin platform has gained considerable traction in the markets of France and Brazil, particularly in vertical private clinics, clinical trials, the public health sector, and the occupational health space.

Fabrice Pakin, CEO and Co-founder of Tech2heal, expressed his excitement about the remarkable traction gained by the Alakin Digital Health Platform since its MVP release in January. He shared, "We are thrilled to witness the tremendous response that the Alakin Digital Health Platform has received. Since its launch, we have successfully introduced Alakin to 13 diverse potential customers across the healthcare industry, ranging from startups to large corporations. Each of these 13 introductions have yielded significant business opportunities, already resulting in several signed commercial contracts and numerous agreements to conduct pilot testing of our platform. The widespread adoption by private clinics, integration in clinical trials, deployment in popular health centers, and application in occupational health further validate the transformative capabilities of Alakin across various healthcare domains."

Vertical private clinics have particularly embraced the Alakin platform, leveraging its high level of configurability to create tailored care pathways for different conditions based on their specific organizational needs. The platform's patient engagement features and AI-based administrative task automation contribute to more efficient and engaging healthcare experiences for both patients and care team members.

In the realm of clinical trials, the Alakin platform has been chosen as the backbone for a comprehensive 5-year study aimed at improving the health of the population aged between 50 and 70. By facilitating remote patient monitoring and telehealth services, the platform enables researchers to collect valuable data and provide proactive care, ultimately enhancing the well-being of study participants.

In Brazil's public health sector, the Alakin platform has been deployed in popular health centers in a large city, leading to enhanced population health initiatives and better access to healthcare services. The platform's capabilities contribute to improved health outcomes for the community, addressing critical healthcare challenges.

Moreover, the Alakin platform is gaining significant traction in the occupational health space, where it addresses the growing issue of absenteeism. Employers increasingly recognize the value of proactive health and quality-of-life policies, and Alakin provides a powerful solution for managing and improving employee health.

About Tech2heal https://www.tech2heal.com/
Tech2heal's Alakin Digital Health Platform is at the forefront of transforming healthcare delivery, empowering healthcare professionals, researchers, and institutions with advanced tools and automation. The platform's AI-powered capabilities facilitate a shift towards patient-centered care, improving outcomes and alleviating the global scarcity of healthcare professionals.

About AI/ML Innovations Inc. https://aiml-innovations.com/
AI/ML Innovations Inc. has realigned its business operations to capitalize on the burgeoning fields of artificial intelligence (AI) and machine learning (ML), with an initial investment focus on emerging digital health and wellbeing companies that leverage AI, ML, cloud computing and digital platforms to drive transformative healthcare management solutions and precision support delivery across the health continuum. Through strategic partnerships with Health Gauge (95.2% owned by AIML), Tech2Heal (up to 22% ownership rights, with 12.44% currently owned by AIML), AI Rx Inc. (70% owned by AIML) and other planned accretive investments, the Company continues to capitalize on expanding growth areas, to the benefit of all the Company's stakeholders. AI/ML's shares are traded on the Canadian Securities Exchange under the symbol "AIML", the OTCQB Venture Market under "AIMLF", and the Frankfurt Stock Exchange under "42FB".

On behalf of the Board of Directors
Tim Daniels, Executive Chairman

For more information about AI/ML Innovations:
For detailed information please see AI/ML's website or the Company's filed documents at www.sedar.com.
For further information, contact: Blake Fallis at (778) 405-0882 or This email address is being protected from spambots. You need JavaScript enabled to view it..

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

For AI/ML Innovations Investors
Certain statements made in this press release that are not based on historical information are forward-looking statements that involve substantial known and unknown risks and uncertainties. This press release contains express or implied forward-looking statements relating to, among other things, AI/ML Innovations' expectations concerning management's plans, objectives and strategies, including strategies for defending the Company's intellectual property. These statements are neither promises nor guarantees but are subject to a variety of risks and uncertainties, many of which are beyond our control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. AI/ML Innovations Inc. undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise except as expressly required by applicable securities law. Further information regarding the uncertainties and risks can be found in the disclosure documents filed by AI/ML with the securities regulatory authorities, available at www.sedar.com.